GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (NAS:SYBX) » Definitions » Enterprise Value

SYBX (Synlogic) Enterprise Value : $-1.61 Mil (As of Dec. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Synlogic Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Synlogic's Enterprise Value is $-1.61 Mil. Synlogic's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-44.20 Mil. Therefore, Synlogic's EV-to-EBIT ratio for today is 0.04.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Synlogic's Enterprise Value is $-1.61 Mil. Synlogic's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-43.45 Mil. Therefore, Synlogic's EV-to-EBITDA ratio for today is 0.04.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Synlogic's Enterprise Value is $-1.61 Mil. Synlogic's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $2.78 Mil. Therefore, Synlogic's EV-to-Revenue ratio for today is -0.58.


Synlogic Enterprise Value Historical Data

The historical data trend for Synlogic's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synlogic Enterprise Value Chart

Synlogic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.31 4.84 60.68 -6.61 4.90

Synlogic Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.29 4.90 2.97 -2.42 -1.96

Competitive Comparison of Synlogic's Enterprise Value

For the Biotechnology subindustry, Synlogic's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synlogic's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synlogic's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Synlogic's Enterprise Value falls into.



Synlogic Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Synlogic's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Synlogic's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synlogic  (NAS:SYBX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Synlogic's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-1.611/-44.196
=0.04

Synlogic's current Enterprise Value is $-1.61 Mil.
Synlogic's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.20 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Synlogic's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=-1.611/-43.446
=0.04

Synlogic's current Enterprise Value is $-1.61 Mil.
Synlogic's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.45 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Synlogic's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-1.611/2.777
=-0.58

Synlogic's current Enterprise Value is $-1.61 Mil.
Synlogic's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synlogic Enterprise Value Related Terms

Thank you for viewing the detailed overview of Synlogic's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Synlogic Business Description

Traded in Other Exchanges
Address
301 Binney Street, Suite 402, Cambridge, MA, USA, 02142
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Executives
Antoine Awad officer: Chief Operating Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Vangsted Jensen officer: Chief Financial Officer 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Aoife Brennan officer: Chief Medical Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Lisa Kelly-croswell director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Michael F. Burgess director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Richard P Shea director C/O MOMENTA PHARMACEUTICALS, INC., 43 MOULTON STREET, CAMBRIDGE MA 02138
Gregg Beloff officer: See Remarks C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Richard J. Riese officer: Chief Medical Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Ginkgo Bioworks, Inc. 10 percent owner 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Scott Eric Plevy officer: Chief Scientific Officer 301 BINNEY STREET, #402, C/O SYNLOGIC, INC., CAMBRIDGE MA 02142
Paul Francis Miller officer: Chief Scientific Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Patricia N. Hurter director C/O SYNLOGIC, INC., 301 BINNEY ST., SUITE 402, CAMBRIDGE MA 02142
Andrew Gengos officer: See Remarks 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Todd Shegog officer: See Remarks 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139

Synlogic Headlines

From GuruFocus

Synlogic Inc at Jefferies Healthcare Conference Transcript

By GuruFocus Research 02-09-2024

Synlogic Inc at Virtual Investor Conferences Transcript

By GuruFocus Research 02-09-2024

Q4 2019 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Synlogic Inc Corporate Update Transcript

By GuruFocus Research 02-09-2024

Synlogic Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-09-2024

Q2 2022 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2021 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2020 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024